Get the Stockscreener App
4.22
4.09%
-0.18
Quince Therapeutics Inc stock is traded at $4.22, with a volume of 953.67K.
It is down -4.09% in the last 24 hours and up +146.78% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$4.40
Open:
$4.41
24h Volume:
953.67K
Relative Volume:
1.61
Market Cap:
$234.98M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-5.0238
EPS:
-0.84
Net Cash Flow:
$-18.45M
1W Performance:
+5.24%
1M Performance:
+146.78%
6M Performance:
+251.67%
1Y Performance:
+106.86%
1-Day Range:
$4.20
$4.5499
1-Week Range:
$3.59
$4.5499
52-Week Range:
$0.7203
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
4.22 | 245.00M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Citizens reiterates Market Outperform rating on Quince Therapeutics stock By Investing.com - Investing.com Canada
Quince Therapeutics publishes early-stage data on eDSP drug delivery system - Investing.com Nigeria
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - BioSpace
Citizens reiterates Market Outperform rating on Quince Therapeutics stock - Investing.com India
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonar - pharmiweb.com
Quince Therapeutics (QNCX) Publishes Promising Early Clinical Study Results - GuruFocus
Check out these key findings about Quince Therapeutics Inc (QNCX) - setenews.com
Trading Action: Is Quince Therapeutics Inc stock a safe buy before earnings2025 Price Momentum & Accurate Trade Setup Notifications - moha.gov.vn
Quince Therapeutics, Inc. (QNCX) -11.5% in After-hours: No Clear Catalyst Driving Decline - Stocks Telegraph
Quince Therapeutics, Inc. (QNCX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why Quince Therapeutics Inc. stock is trending among retail traders2025 Performance Recap & Real-Time Buy Signal Alerts - Newser
Why Quince Therapeutics Inc. stock remains resilientWeekly Investment Recap & Weekly Top Stock Performers List - Newser
Quince Therapeutics (QNCX) Stock Analysis Report | Financials & Insights - Benzinga
Prepare Yourself for Liftoff: Quince Therapeutics Inc (QNCX) - Setenews
Quince Therapeutics Stock Surges 105%, With A 8-Day Winning Spree - Trefis
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Consensus Target Price from Analysts - Defense World
Quince Therapeutics, Inc. (QNCX) 18.8% in Intraday Trading: Surge Amid Upcoming Investor Events - Stocks Telegraph
Quince Therapeutics Stock Rockets 59% With 7-Day Winning Streak - Trefis
Quince Therapeutics: Could NEAT Phase 3 Data Deliver The First Therapy For Ataxia-Telangiectasia? - RTTNews
Adversity is less terrifying than hope: Quince Therapeutics Inc (QNCX) - Setenews
EBITDA per share of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics to Participate at Investor Events in December 2025 - Markets Financial Content
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Quince Therapeutics Inc. stock a dividend growth opportunity2025 Historical Comparison & Growth Oriented Trade Recommendations - newser.com
A new trading data show Quince Therapeutics Inc (QNCX) is showing positive returns. - setenews.com
Can Quince Therapeutics Inc. stock weather global recessionWeekly Stock Recap & Detailed Earnings Play Alerts - newser.com
Sentiment analysis tools applied to Quince Therapeutics Inc.Quarterly Portfolio Report & Weekly High Conviction Ideas - newser.com
How analysts rate Quince Therapeutics Inc. stock todayM&A Rumor & Low Risk Entry Point Tips - newser.com
Statistical indicators supporting Quince Therapeutics Inc.’s strengthGDP Growth & Technical Entry and Exit Alerts - newser.com
Can Quince Therapeutics Inc. stock double in next 5 yearsMarket Trend Review & Weekly Hot Stock Watchlists - newser.com
Combining machine learning predictions for Quince Therapeutics Inc.Global Markets & Daily Chart Pattern Signal Reports - newser.com
Is Quince Therapeutics Inc. stock a good choice for value investorsMarket Risk Summary & Risk Managed Investment Strategies - newser.com
How interest rate cuts could boost Quince Therapeutics Inc. stockShort Setup & Daily Oversold Stock Bounce Ideas - newser.com
What indicators show strength in Quince Therapeutics Inc.July 2025 Levels & Weekly High Return Opportunities - newser.com
Is Quince Therapeutics Inc. stock oversold or undervaluedJuly 2025 Price Swings & Reliable Breakout Forecasts - newser.com
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):